It is trading at $30.05 which is well above the 50 day moving average which is $26.22 and which is significantly above the 200 day moving average of $25.14. The 50 day moving average went up $3.83 or +14.59% and the 200 day average went up by +19.54%. Trading volume for Surmodics, Inc. was 55K in the last trading session. Shares saw a steep increase in trading volume of 10.49% over the normal average daily volume.
Traders are more bullish on Surmodics, Inc. of late at least if you consider the change in short interest. The stock realized a fall in short interest between August 15, 2017 and August 31, 2017 of -5.26%. Short interest decreased 25,917 over that period. The days to cover decreased to 15.0 and the short interest percentage is 0.04% as of August 31.
Additionally, here are a few investment firms who have increased or decreased their stake in (SRDX). Ubs Group Ag added to its holdings by buying 1,161 shares an increase of 2,638.6% as of 06/30/2017. Ubs Group Ag now holds 1,205 shares worth $34,000. The value of the position overall is up by 3,300.0%. As of the end of the quarter Allianz Asset Management Gmbh had disposed of 249 shares trimming its position 0.2%. The value of the company’s investment in Surmodics, Inc. increased from $2,530,000 to $2,954,000 a change of 16.8% quarter over quarter.
Murphy Pohlad Asset Management LLC grew its position by buying 350 shares an increase of 0.5%. Murphy Pohlad Asset Management LLC owns 64,500 shares with a value of $1,815,000. The total value of its holdings increased 17.7%. As of quarter end Two Sigma Advisers, Lp had sold a total of 9,254 shares trimming its holdings by 23.9%. The value of the total investment in Surmodics, Inc. went from $932,000 to $830,000 a change of $102,000 for the reporting period.
On July 14, 2017 Lake Street began coverage of the stock with an initial rating of “Buy”. On June 27 analysts at Aegis Capital added the stock to its research portfolio with a rating of “Buy”.
The company currently has a P/E ratio of 65.47 and the market cap is 393.93M. In the last earnings report the EPS was $0.46 and is projected to be $0.31 for the current year with 13,109,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $0.02 and the next full year EPS is projected to be $0.23.
Surmodics, Inc., launched on June 27, 1979, is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Business’s business segments partner with medical device, diagnostic and life science companies to develop and commercialize products designed to improve patient diagnosis and treatment. As of September 30, 2016, the Company had over 150 licensed product classes (customer products utilizing Surmodics technology) in the market generating royalties and over 100 customer product classes incorporating its technology in various stages of pre-commercialization..